Pharmacotherapy of gastro-oesophageal reflux disease in children: Focus on safety

Expert Opinion on Drug Safety

Volumn 1, Issue 4, 2002, Pages 355-364

  Vandenplas, Yvan ^a   Badriul, Hegar ^a   Salvatore, Sylvia ^a   Hauser, Bruno ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

antireflux surgery; antiregurgitation formula; baby milk; bean gum; cisapride; domperidone; erythromycin; esomeprazole; gastro oesophageal reflux; H2 receptor antagonistmetoclopramide; Nissen intervention; omeprazole; prokinetic; proton pump inhibitor (PPI); ranitidine; side effect

Indexed keywords

ANTIULCER AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP;

BODY POSTURE; CHILD; DRUG ANTAGONISM; EXPERT WITNESS; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SAFETY;

ANTI-ULCER AGENTS; CHILD; CISAPRIDE; EXPERT TESTIMONY; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; PRONE POSITION; PROTON PUMPS; QUALITY OF LIFE; SAFETY;

EID: 0042235467     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.4.355     Document Type: Review

References (133)

1. DORLOCHTER L, KOLSRUD E, OLAFSDOTTIR E, FLUGE G, ROSENDAHL K, HATLEBAKK J: [Oesophageal stricture as a complication of gastroesophageal reflux in children]. Tidsskr. Nor. Laegeforen. (2000) 120:187-189. Norwegian.
2. WEBB D: GERD warrants increased physician appreciation and improved treatment. Postgrad. Med. (2001) 10:5-10.
3. STEWART AL, GREENFIELD S, HATS RD: Functional status and well-being in patients with chronic conditions. JAMA (1989) 262:907-913.
4. ENCK P, DUBOIS D, MARQUIS P: Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastrointestinal Surveillance Study (DIGEST). Scand. J. Gastroenterol. (1999) 231(Suppl.):S48-S54.
5. MASON DB: Gastroesophageal reflux in children: a guide for the advanced practice nurse. Nurs. Clin. North Am. (2000) 35:15-36.
6. ORENSTEIN SR, SHALABY TM, COHN J: Reflux symptoms in 100 normal infants: diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin. Pediatr. (1996) 35:607-614. (Pubitemid 27014639)
7. CHOUHOU D, ROSSIGNOL C, BERNARD F: [Gastroesophageal reflux in screening centers in children under 4 years of age]. Arch. Franç. Pédiatr. (1992) 49:843-845. French.
8. NELSON SP, CHEN EH, SYNIAR GM et al: Prevalence of symptoms of gastroesophageal reflux in infancy. Arch. Pediatr. Adolesc. Med. (1997) 151:569-572.
9. NELSON SP, CHEN EH, SYNIAR GM et al.: One year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics (1998) 102:E67.
10. WIENBECK M, BARNERT J: Epidemiology of reflux disease and reflux esophagitis. Scand. J. Gastroenterol. (1989) 24:7-13. (Pubitemid 19104696)
11. LEE WS, BEATTIE RM, MEADOWS N, WALKER-SMITH JA: Gastro-oesophageal reflux: clinical profiles and outcome. J. Paediatr. Child Health (1999) 35:568-571.
12. TOLAYMAT N, CHAPMAN DM: Gastroesophageal reflux disease in children older than two years of age. W. V Med. J. (1998) 94:22-25.
13. TREEM W, DAVIS P, HYAMS J: Gastroesophageal reflux in the older child: presentation, response to treatment, and long-term follow-up. Clin. Pediatr. (1991) 30:435-440.
14. LOOF L, GOTELL P, ELFBERG B: The incidence of reflux oesophagitis. Scand. J. Gastroenterol (1993) 28:113-118.
15. NANDURKAR S, TALLEY NJ: Epidemiology and natural history of reflux disease. Ballieres Best Pract. Res. Clin. Gastroenterol (2000) 14:743-757.
16. DE CAESTECKER J: Oesophagus: heartburn. Br. Med. J. (2001) 323:736-739.
17. VOUTILAINEN M, SIPPONEN P, MACKLIN JP: Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion (2000) 61:6-13. (Pubitemid 30098953)
18. MCDOUGALL NJ, JOHNSTON BT, KEE F: Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut (1996) 38:481-486. (Pubitemid 26111364)
19. CARRE I: The natural history of the partial thoracic stomach ('hiatal hernia') in children. Arch. Dis. Child. (1959) 34:344-353.
20. NO AUTHORS LISTED: French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease 'Diagnosis and Treatment': report of a meeting held in Paris, France, on 21-22 January 1999. The Jury of the consensus agreement. Eur. J. Gastroenterol. Hepatol. (2000) 12:129-137.
21. HASSALL E, DIMMICK JE, MAGEE JF: Adenocarcinoma in childhood Barrett's esophagus: case documentation and the need for surveillance in children. Am. J. Gastroenterol. (1993) 88:282-288. (Pubitemid 23053487)
22. HASSALL E: Co-morbidities in childhood Barrett's esophagus. J. Pediatr. Gastroenterol. Nutr. (1997) 25:255-260. (Pubitemid 27375414)
23. ROMERO Y, CAMERON AJ, LOCKE GR: Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal carcinoma. Gastroenterology (1997) 113:1449-1456. (Pubitemid 27461230)
24. KRUG E, BERGMEIJER JH, DEES J: Gastroesophageal reflux and Barrett's esophagus in adults born with esophageal atresia. Am. J. Gastroenterol. (1999) 94:2825-2828. (Pubitemid 29485396)
25. DAHMS BB, ROTHSTEIN FC: Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology (1984) 86:318-323. (Pubitemid 14218585)
26. SONNENBERG A, EL-SERAG HB: Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J. Biol. Med. (1999) 72:81-92. (Pubitemid 30215107)
27. DE KOSTER E: Adverse events of HP eradication: long term negative consequences of HP eradication. Acta Gastroenterol. Belg. (1998) 61:350-351. (Pubitemid 28473337)
28. LAGERGREN J, BERGSTROM R, LINDGREN A, NYRÉN O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl. J. Med. (1999) 340:825-831. (Pubitemid 29142625)
29. KAYANRD A, FLORA K: Gastroesophageal reflux disease. Control of symptoms, prevention of complications. Postgrad. Med. (2001) 110:42-44.
30. VANDENPLAS Y, BELLI D, BENHAMOU P et al: A critical appraisal of current management practicies for infant regurgitation-recommendations of a working party. Eur. J. Pediatr. (1997) 156:343-357.
31. EWER AK, JAMES ME, TOBIN JM: Prone and left lateral positioning reduce gastro-oesophageal reflux in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. (1999) 81 :F201-F205. (Pubitemid 29503329)
32. KHOSHOO V, ROSS G, BROWN S, EDELL D: Smaller volume, thickened formulas in the management of gastroesophageal reflux in thriving infants. J. Pediatr. Gastroenterol. Nutr. (2000) 31:554-556.
33. CARROLL AE, GARRISON MM, CHRISTAKIS DA: A systematic review of nonpharmacological and nonsurgical therapies for gastroesophageal reflux in infants. Arch. Pediatr. Adolesc. Med. (2002) 156:109-113. (Pubitemid 34111465)
34. BOSSCHER D, VAN CAILLIE-BERTRAND M, VAN DYCK K, ROBBERECHT H, VAN CAUWENBERGH R, DEELSTRA H: Thickening of infant formula with digestible and indigestible carbohydrate availability of calcium, iron and zinc in vitro. J. Pediatr. Gastroenterol. Nutr. (2000) 30:373-378. (Pubitemid 30350923)
35. AGGETT PJ, AGOSTONI C, GOULET O et al: Antireflux or antiregurgitation milk products for infants and young children: a commentary by the ESPGHAN Committee on nutrition. J. Pediatr. Gastroenterol. Nutr. (2002) 34:496-498. (Pubitemid 34596214)
36. VANDENPLAS Y: Clinical use of cisapride and its risk-benefit in paediatric patients. Eur. J. Gastroenterol. Hepatol. (1998) 10:871-881. (Pubitemid 28493265)
37. ARAVINDHAN N, CHISHOLM DG: Sulfhemoglobinemia presenting as pulse oximetry desaturations. Anesthesiology (2000) 93:883-884.
38. CINQUETTI M, BONETTI P, BERTAMINI P: Current role of antidopaminergic drugs in pediatrics. Pediatr. Med. Chir. (2000) 22:1-7. (Pubitemid 32410330)
39. CHOU CC, WU D: Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gubng Med. J. (2001) 4:805-809.
40. PATTERSON D, ABELL T, ROTHSTEIN R, KOCH K, BRNETT J: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am. J. Gastroenterol. (1999) 94:1230-1204.
41. BARONE JA: Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann. Pharmacother. (1999) 33:429-40. (Pubitemid 29215810)
42. SOYKAN I, SAOSIEK I, MCCALLUM RW: The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am. J. Gastroenterol. (1997) 92:976-980. (Pubitemid 27237588)
43. LU F, WU H, ZHANG K, LI D: [Domperidone and hyperprolactinemia]. Human Yi Ke Da Xue Xue Bao (1998) 23:100-102. Chinese.
44. BRUERA E, VILLAMAYOR R, ROCA E, BARUGEL M, TRONGE J, CHACON R: QT interval and ventricular fibrillation with i.v. domperidone. Cancer Treat. Rep. (1986) 70:545-546. (Pubitemid 16116472)
45. DROLET B, ROUSSEAU G, DALEAU P, CARDINAL R, TURGEON J: Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation (2000) 102:1883-1885.
46. OSBORNE RJ, SLEVIN ML, HUNTER RW: Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum. Toxicol. (1985) 4:617-626.
47. CAMERON HA, REYNTJES AJ, LAKE-BAKAAR G: Cardiac arrest after treatment with intravenous domperidone. Br. Med. J. (1985) 290:160. (Pubitemid 15122971)
48. QUINN N, PARKES D, JACKSON G: Cardiotoxicity of domperidone. Lancet (1985) 2:724. (Pubitemid 15244969)
49. OSBORNE RJ, SLEVIN ML, HUNTER RW: Cardiotoxicity of intravenous domperidone. Lancet (1985) 2:385. (Pubitemid 15012970)
50. ROUSSAK JB, CAREY P, PARRY H: Cardiac arrest after treatment with intravenous domperidone. Br. Med. J. (1984) 289:1579. (Pubitemid 15220621)
51. GIACCONE G, BERLOTTO O, CALCIATI A: Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet (1984) 2:1336-1337. (Pubitemid 15176817)
52. JOSS RA, GOLDHIRSCH A, BRUNNER KW: Sudden death in a cancer patient on high dose domperidone. Lancet (1982) 1:1019. (Pubitemid 12146415)
53. MAHON BE, ROSENMAN MB, KLEIMAN MB: Maternal and infant use of erythromycin and other macroliden antibiotics as risk factors for infantile hypertrophic pylori stenosis. J. Pediatr. (2001) 139:380-384. (Pubitemid 32889514)
54. BRIXIUS B, LINDINGER A, BAGHAI A, LIMBACH HG, HOFFMANN W: [Ventricular tachycardia after erythromycin administration in a newborn with congenital AV-block]. Klin. Padiatr. (1999) 211:465-468. German. (Pubitemid 29535835)
55. MISHRA A, FRIEDMAN HS, SINHA AK: The effects of erythromycin on the electrocardiogram. Chest (1999) 115:983-986. (Pubitemid 29193665)
56. GUERIN JM, LEIBINGER F: Why not use erythromycin in GI motility. Chest (2002) 121:301-302.
57. GAY K, BAUGHAN W, MILLER J: The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J. Infect. Dis. (2000) 182:1417-1424.
58. VANDENPLAS Y, BELLI DC, BENATAR A et al: The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. (1999) 28:518-528.
59. VANDENPLAS Y AND THE ESPGHAN CISAPRIDE PANEL: Current pediatric indications for cisapride. J. Pediatr. Gastroenterol. (2000) 31:480-489.
60. GONZALES GALICIA JA, JUAREZ GALINDO S, SUARIZ MORAN E: Clinical and endoscopic evaluation of the efficacy of cisapride as compared to metoclopramide in gastroesophageal reflux in children. Invest. Med. Int. (1992) 19:1-8.
61. BRAVO MATUS CA, FLORES RM: Comparative study between cisapride and metoclopramide in newborns with gastroesophageal reflux. Invest. Med. Int. (1995) 22:3-7.
62. RODE H, MILLAR AJW, MELIS J, CYWES S: Esophageal assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide. J. Pediatr. Surg. (1987) 22:931-934. (Pubitemid 17156498)
63. HARE C, HALLIGAN S, BARTRAM CI, PLATT K, RALEIGH G: Cisapride or metoclopramide to accelerate small bowel transit during barium follow-through examination? Abdom. Imaging (2000) 25:243-245. (Pubitemid 30304978)
64. AUGOOD C, MACLENNAN S, GILBERT R, LOGAN S: Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst. Rev. (2000) 3:CD002300.
65. SHULMAN RJ: Report from the NASPGN therapeutics subcommittee. Cisapride and the attack of the P450s. J. Pediatr. Gatsroenterol Nutr. (1996) 23:395-397.
66. DESTA Z, ZOUKHOVA N, MAHAL SK, FLOCKHART DA: Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab. Dispos. (2000) 28:789-800. (Pubitemid 30470829)
67. VISKIN S: Long QT syndromes and torsades de pointes. Lancet (1999) 354:1625-1633.
68. TONINI M, DE PONTI F, DI NUCCI A, CREMA F: Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment. Pharmacol. Ther (1999) 13:1585-1591. (Pubitemid 30009075)
69. ENRIQUEZ A, BOLISETTY S, PATOLE S, GAARVEY PA, CAMPBELL PJ: Randomised controlled trial of cisapride in feed intolerance in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. (1998) 79:F110-F113. (Pubitemid 28419170)
70. WAYHS ML, BARROS JP, SILVA ML, FERNANDES VR, LOPES SL: The QT interval in children receiving cisapride. J. Pediatr. Gastroenterol. Nutr. (2000) 31(Suppl. 2):S247-S248.
71. ALONSO E, AL-TAWIL YS, SIMAKAJOMBOON R, NOEL RA: Evaluation of QTc changes in pediatric patients treated with cisapride. J. Pediatr. Gastroenterol. Nutr. (2000) 31(Suppl. 2):S35.
72. LEVINE A, FOGELMAN R, SIROTA L, ZANGEN Z, SHAMIR R, DINARI G: QT interval in children and infants receiving cisapride. Pediatrics (1998) 101:E9. Abstract.
73. LANDER A, SESAI A: The risks and benefits of cisapride in premature neonates, infants and children. Arch. Dis. Child. (1998) 79:469-470. (Pubitemid 28539099)
74. HILL SL, EVANGELISTA JK, PIZZI AM, MOBASSALEH M, FURTON DR, BERUL CI: Proarrhythmia associated with cisapride in children. Pediatrics (1998) 101:1053-1056. (Pubitemid 28248893)
75. VA N HA A RS T AD, VA N T KLOOSTER GA, VAN GERVEN JM et al.: The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin. Pharmacol. Ther. (1998) 64:542-546. (Pubitemid 28531598)
76. WARD RM, LEMONS JA, MOLTENI RA: Cisapride: a survey of the frequency of use and adverse events in premature newborns. Pediatrics (1999) 103:469-472. (Pubitemid 29274544)
77. LEVY J, HAYES C, KERN J et al.: Does cisapride influence cardiac rhythm? Results of a US multicenter, double-blind, placebo controlled pediatric study. J. Pediatr. Gastroenterol. Nutr. (2000) 31(Suppl. 2):S100.
78. TAHIRIC : Prepulsid et allongement de l'espace QT, J. Pédiatr. Puériculture, 1998, 11, 422-428.
79. HANSON R, BROWNE G, FASHER B, MCASKILL M, MORONEY P, HAWKER R: Cisapride-prolonged QT-interval: too much of a good thing! J. Pediatr. (1997) 130:164-166. (Pubitemid 27492741)
80. LUPOGLAZOFF JM, BEDU A, FAURE C et al.: Long QST syndrome under cisapride in neonates and infants. Arch. Pediatr. (1997) 4:509-514. (Pubitemid 27282867)
81. TUTAR HE, KANSU A, KALAYCI AG, GIRGIN N, ATALY S, IMAMOGLU A: Effects of cisapride on ventricular repolarization in children. Acta Paediatr. (2000) 89:820-823. (Pubitemid 30622583)
82. SEMAMA DS, BERNARDINI S, LOUF S, LAURENT-ATTHALIN B, GUYON JB: Effects of cisapride on QTc interval in term neonates. Arch. Dis. Child. Fetal Neonatal Ed. (2001) 84:F44-F46. (Pubitemid 32060171)
83. BENATAR A, FEENSTRA A, DE CRAENE T, VANDENPLAS Y: QTc interval in infants and serum concentrations. J. Pediatr. Gastroenterol. Nutr. (2001) 33:41-46.
84. KIVISTO KT, LILJA JJ, BACKMAN JT, NEUVONEN PJ: Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin. Pharmacol. Ther. (1999) 66:448-453.
85. NAPOLITANO C, SCHWARTZ PJ, BROWN AM et al.: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. (2000) 11:691-696. (Pubitemid 30397542)
86. WALKER AM, SZNEKE P, WEATHERBY LB et al.: The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am. J. Med. (1999) 107:356-362. (Pubitemid 29465814)
87. FLOCKHART DA, DESTA Z, MAHAL SK: Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin. Pharmacokinet. (2000) 39:295-309.
88. BACHMANN KA, SULLIVAN TJ, JAUREGUI L, REESE J, MILLER K, LEVINE L: Drug interactions of H2-receptor antagonists. Scan. J. Gastroenterol. (1994) 206(Suppl.):14-19.
89. PAUL K, REDMAN CM, CHEN M: Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment. Pharmacol. Ther. (2001) 15:1571-1577. (Pubitemid 32912399)
90. SABESIN SM: Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Aliment. Pharmacol. Ther. (1993) 7(Suppl. 2):35-40. (Pubitemid 23198351)
91. KELLY DA: Do H2 receptor antagonists have a therapeutic role in childhood? J. Pediatr. Gastroenterol. (1994) 19:270-276. (Pubitemid 24299642)
92. ADACHI N, SEYFRIED FJ, ARAI T: Blockade of central histaminergic H2-receptors aggravates ischemic neuronal damage in gerbil hippocampus. Crit. Care Med. (2001) 29:1189-1194. (Pubitemid 32554333)
93. DUBOIS A, BROUSSINE L, BLAYO M, RICHE C: Lethargy in the course of treatment with ranitidine in a newborn infant. Pediatrie (1993) 48:335-336.
94. EMOVON OE, KING JA, HOLT CO, BROWNE BJ: Ranitidine induced acute interstitial nephritis in a cadaveric renal allograft. Am. J. Kidney Dis. (2001) 38:169-172. (Pubitemid 32611774)
95. BOEHNING W: Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids. Eur. J. Clin. Pharmacol. (1990) 38:43-45. (Pubitemid 20050809)
96. ALLIET P, DEVOS E: Ranitidine-induced bradycardia in a neonate-secondary to a congenital long QT interval syndrome. Eur. J. Pediatr. (1993) 152:933-934.
97. HU WH, WANG KY, HWANG DS, TING CT, WU TC: Histamine 2 receptor blocker-ranitidine and sinus mode dysfunction. Zhonghua Yi Xue Za Zhi (1997) 60:1-5.
98. NAULT MA, MILNE B, PARLOW JL: Effects of the selective H1 and H2 histamine receptor antagonists loretadine and ranitidine on autonomic control of the heart. Anesthesiology (2002) 96:336-341. (Pubitemid 34121742)
99. OOIE T, SAAIKAWA T, HARA M, ONO H, SEIKE M, SAKATA T: H2-blocker modulates heart rate variability. Heart Vessels (1999) 14:137-142. (Pubitemid 30008997)
100. BASIT AW, NEWATON JM, LACEY LF: Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int. J. Pharm. (2002) 237:23-33. (Pubitemid 34310476)
101. COTHRAN DS, BOROWITZ SM, SUTPHEN JL, DUDLEY SM, DONOWITZ LG: Alteration of normal gastric flora in neonates receiving ranitidine. J. Perinatol (1997) 17:383-388. (Pubitemid 127454932)
102. MESSORI A, TRIPPOLI S, VAIANI M, GORINI M, CORRADO A: Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. Br. Med. J. (2000) 321:1103-1106.
103. HUANG JQ, HUNT RH: Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract. Res. Clin. Gastroenterol. (2001) 15:355-370. (Pubitemid 32590872)
104. LONDONG W, PHILLIPS J, JOHNSON NJ, WOOD JR: The effect of combined therapy with ranitidine and pirenzipine in the treatment of reflux esophagitis. Aliment. Pharmacol. Ther (1992) 6:609-618.
105. VAKIL NB, SHAKER R, JOHNSON DA et al: The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol. Ther. (2001) 15:927-935. (Pubitemid 32578963)
106. JONES R, BYTZER P: Acid suppression in the management of gastro-oesophageal reflux disease-an appraisal of treatment options in primary care. Aliment. Pharmacol. Ther. (2001) 16:765-771.
107. FERRON GM, PRESTON RA, NOVECK RJ et al.: Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin. Ther. (2001) 23:1180-1192. (Pubitemid 32804113)
108. JAMES LP, KEARNS GL: Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin. Pharmacokinet. (1996) 31:103-110. (Pubitemid 26252688)
109. ZIMMERMANN AE, WALTERS JK, KATONA BG, SOUNEY PE, LEVINE D: A review of omeprazole use in the treatment of acid-related disorders in children. Clin. Ther. (2001) 23:660-679. (Pubitemid 32472600)
110. LEUFKANS H, CLAESSENS A, HEERDINK E, VAN EIJK J, LAMERS CB: A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment. Pharmacol. Ther. (1997) 11:887-897.
111. CASTOT A, BIDAULT I, DAHAN R, EFTHYMIOU ML: [Evaluation of unexpected and toxic effects of omeprazole A90 reported to the regional centers of pharmacovigilance during the first 22 postmarketing months]. Therapie (1993) 48:469-474. French.
112. BERARDI RR: Proton pump inhibition. An effective, safe approach to GERD management. Postgrad. Med. (2001) Spec. No:24-35.
113. ANDERSSON T, HANSSAN-ALIN M, HASSELGREN G, ROHSS K: Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:523-537. (Pubitemid 32743165)
114. TER HEIDE H, HENDRIKS HJ, HEIJMANS H et al.: Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B12 deficiency? J. Pediatr. Gastroenterol. Nutr. (2001) 33:342-345. (Pubitemid 32947343)
115. SINGH P, INDARAM A, GREENBERG R, VISVALINGAM V, BANK S: Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J. Gastroenterol. (2000) 6:789-792. (Pubitemid 32015791)
116. NAUNTON M, PETERSON GM, BLEASEL MD: Overuse of proton pump inhibitors. J. Clin. Pharm. Ther. (2000) 25:333-338.
117. CULY CR, BHANA N, PLOSKER GL: Ondansetron: a review of its use as an antiemetic in children. Paediatr. Drug s (2001) 3:441-479. (Pubitemid 32589000)
118. FLEMING GF, VOKES EE, MCEVILLY M, JANISCH L, FRANCHER D, SMALDONE L: Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemother. Pharmacol. (1991) 28:226-227.
119. TALLEY NJ, VERLINDEN M, SNAPE W et al.: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. (2000) 14:1653-1661. (Pubitemid 32011739)
120. JADCHERLA SR, KLEE G, BERSETH CL: Regulation of migrating motor complexes by motilin and pancreatic polypeptide in human infants. Pediatr. Res. (1997) 42:365-369. (Pubitemid 27362734)
121. BLACKSHAW LA, STAUNTON E, LEHMANN A, DENT J: Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am. J. Physiol. (1999) 277:G867-G874. (Pubitemid 29525939)
122. LIDUMS I, LEHMANN A, CHECKLIN H, DENT J, HOLLOWAY RH: Control of transient lower esophageal sphincter relaxations and reflux by the GABA agonist baclofen in normal subjects. Gastroenterology (2000) 118:7-13. (Pubitemid 30020367)
123. AMARO R, MONTELONGO PC, BARKIN JS: Sucralfate-induced diarrhea in an enterally fed patient. Am. J. Gastroenterol. (1999) 94:2328-2329. (Pubitemid 29374588)
124. GUY C, OLLAGNIER M: Sucralfate and bezoars: data from the system of pharmacologic vigilance and review of the literature. Therapie (1999) 54:55-58. (Pubitemid 29145972)
125. HEMSTREET BA: Use of sucralfate in renal failure. Ann. Pharmacother. (2001) 35:360-364. (Pubitemid 32201721)
126. FONKALSRUD EX, BUSTORFF-SILVA J, PEREZ CA, QUINTERO R, MARTIN L, ATKINSON JB: Antireflux surgery in children under three months of age. J. Pediatr. Surg. (1999) 34:527-531. (Pubitemid 29183779)
127. PEARL RH, ROBIE DK, EIN SH et al.: Complications of gastroesophageal reflux surgery in neurologically impaired versus neurologically normal children. J. Pediatr. Surg. (1990) 25:1169-1173. (Pubitemid 20368648)
128. ALEXANDER F, WYLLIE R, JIROUSEK K, SECIC M, PORVASNIK S: Delayed gastric emptying affects outcome of Nissen fundoplication in neurologically impaired children. Surgery (1997) 122:690-697.
129. SPITZ L, ROTH K, KIELY EM, BRERETON RJ, DRAKE D P, MILLA PJ: Operation for gastro-oesophageal reflux associated with severe mental retardation. Arch. Dis. Child. (1993) 68:347-351. (Pubitemid 23084584)
130. BOOTH MI, JONES L, STRATFORD J, DEHN TC: Results of laparoscopic Nissen fundoplication 8 years after surgery. Br. J. Surg. (2002) 89:476-481. (Pubitemid 34595515)
131. BERGMEIJER JH, HARBERS JS, MOLENAAR JC: Function of pediatric Nissen-Rossetti fundoplication followed up into adolescence and adulthood. J. Am. Coll. Surg. (1997) 184:259-261. (Pubitemid 27113853)
132. ESPOSITO C, MONTUPET P, AMICI G, DESRUELLE P: Complications of laparoscopic antireflux surgery in childhood. Surg. Endosc. (2000) 14:622-624. (Pubitemid 30626212)
133. BURD RS, PRICE MR, WHALEN TV: The role of protective antireflux procedures in neurologically impaired children: a decision analysis. J. Pediatr. Surg. (2002) 37:500-506. (Pubitemid 34188182)